Compared with the other groups, Rapa-SLE-EV treatment inhibited B-cell activation most significantly, as evidenced by the expression of costimulatory molecules CD80 and CD86 (Fig. 8A–D). The gene discussed is CD86; the disease is systemic lupus erythematosus.